Sublingual gland neoplasms: clinicopathological study of 8 cases

• Published in: Medicina oral, patología oral y cirugía bucal Vol. 26; no. 5; pp. e626 - e631
• Main Authors: Gontarz, M., Urbańska-Gąsiorowska, M., Bargiel, J., Gąsiorowski, K., Marecik, T., Szczurowski, P., Zapała, J., Wyszyńska-Pawelec, G.
• Format: Journal Article
• Language: English
• Published: Medicina Oral S.L 01-09-2021
• Subjects: Dentistry
• ISSN: 1698-6946; 1698-4447; 1698-6946
• DOI: 10.4317/medoral.24634

BACKGROUNDSublingual gland neoplasms are very rare and the majority of them are malignant. The aim of this study was to evaluate the clinical course, treatment, and outcomes of these uncommon neoplasms based on the authors' experience and the recent literature. MATERIAL AND METHODSThe medical charts of 8 patients with primary epithelial sublingual gland tumors treated between 1994 and 2020 were reviewed. RESULTSMalignant tumors comprised 75% (6/8) of cases. Adenoid cystic carcinoma was the most common (50%, 3/6) and characterized by high risk of local recurrence and lung metastasis. Pleomorphic adenoma was the only representative of benign tumors with no evidence of local recurrence in follow up. CONCLUSIONSTreatment of choice of sublingual gland tumors is surgery. However, due to the fact that adenoid cystic carcinoma is the most common malignancy with poor prognosis, surgical treatment should be combined with postoperative radiotherapy. Benign sublingual tumors are less common and treatment of choice in these cases is tumor resection together with sublingual gland.